Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Viagra Vision Loss Concern Will Prompt Erectile Dysfunction Class Labeling, Pfizer Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer's review of adverse event reports concludes there is no evidence of increased risk of non-arteritic anterior ischemic optic neuropathy – but the company is agreeing to include rare reports in labeling. Lilly reports a boost in Cialis' market share since late May, when the Viagra safety concerns came to light.
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS062464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel